World Health Organization Issues Alert Over Acute Shortage of Obesity Medications

Less than one in 10 individuals eligible to benefit from obesity jabs like Wegovy can access them, states the global health agency as it releases its first recommendations on the therapies.

With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.

Based on estimates, over two billion will be obese by 2030 without intervention.

"The new guidelines affirms that obesity is a long-term condition that can be managed with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant barriers to broad availability to the jabs that can aid individuals in losing considerable weight, explains the agency.

Skinny Jab Shortage

Even in the present most optimistic scenario, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of the global need, according to the health organization.

The advice encourages governments and firms to expand access, by approaches like licensing agreements.

The intellectual property rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.

How Obesity Jabs Work

The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so users eat less.

Patients usually start to lose weight in the initial weeks of starting on the weekly injections.

Evidence suggests people may see weight return after a year of halting the drug, as their normal hunger resume.

To be above a healthy weight raises your likelihood for developing diseases, such as type 2 diabetes, heart disease, stroke, and some malignancies.

Obesity concerns people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.